The increasing prevalence of retinal vein occlusion, along with expanding geriatric population worldwide, is expected to drive the growth of the retinal vein occlusion treatment market. Additionally, advancements in technology leading to innovative treatment options and a growing focus on research and development activities are further propelling market growth.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Disease Type, Treatment, End-User |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | AbbVie, F. Hoffmann-La Roche., Regeneron Pharmaceuticals, Taiwan Liposome Company,., Aerie Pharmaceuticals, CalciMedica, Outlook Therapeutics,, Kodiak Sciences, Chugai Pharmaceutical, Pfizer |
The high treatment costs and limited reimbursement policies are major restraints hindering market growth for retinal vein occlusion treatment. Additionally, the lack of awareness about the available treatment options among patients in developing regions is also impacting market growth negatively.